Comments
Dr Reddy’s Laboratories and Brisbane-based Alchemia Ltd today announced that the US Food and Drug Administration gave final approval for the launch of their Fondaparinux sodium injection, a bioequivalent generic version of Arixtra in the US market on July 11.
The approval covers 2.5 mg/0.5 ml, 5.0 mg/0.4 ml, 7.5 mg/0.6 ml and 10 mg/0.8 ml doses of the drug in pre-filled, color-coded, single-dose syringes with an automatic needle safety device.
Dr Reddy’s will manufacture Fondaparinux under a licence using a patented process developed by Alchemia, DRL said in a statement.
The US patents on Arixtra expired in 2002, the year before the drug was launched in the US.
Alchemia’s process for the synthesis of Fondaparinux is covered by a patent estate with two issued patents and two pending applications in the US.
The Arixtra brand had US sales of approximately $340 million (year-on-year growth of 16 per cent) for the 12 months ending May, 2011, according to IMS National Sales Perspectives.
“The Fondaparinux approval demonstrates the strong technical capabilities of the teams at Dr Reddy’s and Alchemia. Given that this is a complex generic molecule which is difficult to manufacture at scale, competition is likely to be limited for the foreseeable future,” Dr Reddy’s Vice-Chairman and CEO, Mr G.V. Prasad, said.
“Accordingly, from a commercial perspective, Dr Reddy’s will promptly execute a phased launch that initially plays to our strengths in select wholesale and retail outlets and subsequently enhance share over time in the coming quarters to augment the growing annuity of upsides in our North America generics business,” he said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.